Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
17.54 SEK | +0.23% | +8.81% | +13.45% |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Sales 2024 * | 617M 56.55M | Sales 2025 * | 773M 70.91M | Capitalization | 603M 55.29M |
---|---|---|---|---|---|
Net income 2024 * | -110M -10.09M | Net income 2025 * | -29M -2.66M | EV / Sales 2024 * | 1.45 x |
Net Debt 2024 * | 290M 26.6M | Net Debt 2025 * | 199M 18.25M | EV / Sales 2025 * | 1.04 x |
P/E ratio 2024 * |
-5.5
x | P/E ratio 2025 * |
-20.3
x | Employees | 116 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.49% |
Latest transcript on Orexo AB
1 day | +0.23% | ||
1 week | +8.81% | ||
Current month | +12.58% | ||
1 month | +19.32% | ||
3 months | +23.17% | ||
6 months | +13.45% | ||
Current year | +13.45% |
Managers | Title | Age | Since |
---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 52 | 11-09-30 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 57 | 22-08-31 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 19-04-10 | |
James Noble
CHM | Chairman | 65 | 20-04-15 |
Director/Board Member | 62 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 17.54 | +0.23% | 242 |
24-04-17 | 17.5 | +3.43% | 13,004 |
24-04-16 | 16.92 | +3.30% | 4,463 |
24-04-15 | 16.38 | 0.00% | 6,290 |
24-04-12 | 16.38 | +1.61% | 6,558 |
Delayed Quote Nasdaq Stockholm, April 18, 2024 at 03:22 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.45% | 54.84M | |
+0.52% | 68.09B | |
+11.18% | 9.08B | |
-19.62% | 4.57B | |
+24.23% | 3.9B | |
-0.44% | 3.69B | |
+29.70% | 2.62B | |
-25.01% | 2.34B | |
-28.30% | 2.14B | |
+1.33% | 1.84B |
- Stock Market
- Equities
- ORX Stock